DMKC Advisory Services’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.83M Buy
117,624
+20,584
+21% +$538K 0.53% 52
2026
Q1
$2.72M Buy
97,040
+13,638
+16% +$363K 1.14% 39
2025
Q4
$2.08M Buy
83,402
+10,705
+15% +$270K 0.91% 45
2025
Q3
$1.85M Buy
72,697
+3,677
+5% +$90.8K 0.94% 45
2025
Q2
$1.7M Buy
69,020
+10,679
+18% +$249K 0.89% 49
2025
Q1
$1.48M Buy
58,341
+2,474
+4% +$64.7K 1.33% 39
2024
Q4
$1.48M Buy
+55,867
New +$1.52M 1.34% 39

Other funds holding PFE

DMKC Advisory Services's PFE Position: Q2 2026 in Review

DMKC Advisory Services increased its Pfizer (PFE) stake by 21% in Q2 2026, buying an estimated $538K and bringing the position to 117,624 shares worth $2.83M. The position accounts for 0.53% of the portfolio, ranked #52.

DMKC Advisory Services first reported a position in PFE in Q4 2024 and has held it in 7 quarters since. 631 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • DMKC Advisory Services held 117,624 shares of Pfizer worth $2.83M as of Q2 2026.
  • DMKC Advisory Services bought 20,584 Pfizer shares in Q2 2026, an estimated $538K.
  • Pfizer made up 0.53% of DMKC Advisory Services's portfolio in Q2 2026, its #52 holding.
  • DMKC Advisory Services first reported a position in Pfizer in Q4 2024 and has held it in 7 quarters since.
  • 631 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on DMKC Advisory Services's 13F filing for Q2 2026, filed 7 Jul 2026.